{"id":"061492a0-0b3e-54f7-8944-a07884417c1e","stable_key":"10629adf-a816-5b7b-82db-a76bfbb946f2:bg-dose-did-not-track-response","predicate":"preserves_measured_pool","statement":"One patient developed a dose-limiting toxicity of transient self-limiting hepatic transaminase elevation 5 days after starting beta-glucan at 120 milligrams per kilogram per day, overall 1, 3, 12 and 24 evaluable patients had complete response, partial response, stable and progressive disease respectively at the end of treatment, positive human anti-mouse antibody response and dectin-1 rs3901533 polymorphism were associated with better overall survival, and beta-glucan dose level and serum beta-glucan levels did not correlate with response.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"6f4b8338-9f9a-5729-90b8-1dd4bae480bd","mechanism_event_label":"Across a twentyfold range of doses, how much was taken did not predict who responded; a receptor gene variant did.","subject":{"id":"919e84e7-6b11-59de-a10b-8b844b1e72f3","slug":"yeast-beta-glucan","display_name":"Yeast beta-(1->3)/(1->6)-glucan","entity_type_key":"chemical_species"},"object":{"id":"fae8ae7e-3be1-5692-898a-c3790790bfb5","slug":"objective-response-rate","display_name":"Objective tumour response rate","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"6f4b8338-9f9a-5729-90b8-1dd4bae480bd","stable_key":"10629adf-a816-5b7b-82db-a76bfbb946f2:bg-dose-did-not-track-response-event","event_type":"observed_intervention","label":"Across a twentyfold range of doses, how much was taken did not predict who responded; a receptor gene variant did.","description":"One patient developed a dose-limiting toxicity of transient self-limiting hepatic transaminase elevation 5 days after starting beta-glucan at 120 milligrams per kilogram per day, overall 1, 3, 12 and 24 evaluable patients had complete response, partial response, stable and progressive disease respectively at the end of treatment, positive human anti-mouse antibody response and dectin-1 rs3901533 polymorphism were associated with better overall survival, and beta-glucan dose level and serum beta-glucan levels did not correlate with response.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"98a27026-6642-550a-9523-e5d7de9e3367","slug":"clec7a-rs3901533","display_name":"The dectin-1 rs3901533 single nucleotide polymorphism","entity_type_key":"gene"},"role":"associated_genotype","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"711f6659-2384-58ad-a02a-214f73798893","slug":"anti-gd2-antibody-3f8","display_name":"The murine anti-GD2 monoclonal antibody 3F8","entity_type_key":"protein"},"role":"combination_partner","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"b45f0197-4a2c-5f72-a085-20403e9db300","slug":"transaminase-elevation","display_name":"Elevation of alanine and aspartate aminotransferase","entity_type_key":"cellular_process"},"role":"observed_harm","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"117c178c-d74c-5c56-b2d6-d3956ad70c03","slug":"clec7a","display_name":"Dectin-1 / CLEC7A","entity_type_key":"protein"},"role":"host_receptor","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""},{"entity":{"id":"919e84e7-6b11-59de-a10b-8b844b1e72f3","slug":"yeast-beta-glucan","display_name":"Yeast beta-(1->3)/(1->6)-glucan","entity_type_key":"chemical_species"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":4,"notes":""},{"entity":{"id":"fae8ae7e-3be1-5692-898a-c3790790bfb5","slug":"objective-response-rate","display_name":"Objective tumour response rate","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":5,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/glucan-research/34944886.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"ebbaee1e57b37044ff51d85d98d519101169e09a734d420c8bce53faab1d19f0\", \"start_char\": 0, \"end_char\": 1471, \"text_sha256\": \"ebbaee1e57b37044ff51d85d98d519101169e09a734d420c8bce53faab1d19f0\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Phase I dose escalation of oral yeast glucan with an anti-GD2 antibody across cohorts of three to six patients","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Oral yeast beta-glucan escalated from 10 to 200 milligrams per kilogram per day for 17 days with intravenous 3F8 antibody","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"A single-arm phase I with no control for the antibody alone, so the glucan contribution to any response cannot be isolated. Forty-four patients completed 141 cycles and forty were evaluable at end of treatment.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Beta-glucan research collection; topical membership is not evidence of a direct clinical effect, and each preparation is recorded as its own entity with no family link joining any pair.","comparator":null,"unit":null,"notes":"","entity":{"slug":"beta-glucan","display_name":"Beta-glucan","entity_type_key":"chemical_species"}},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Across a twentyfold range of doses, how much was taken did not predict who responded; a receptor gene variant did.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[bg-p34944886] Phase I Trial of Oral Yeast-Derived β-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk Neuroblastoma. (2021). https://pubmed.ncbi.nlm.nih.gov/34944886/ DOI: 10.3390/cancers13246265","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Relapsed or refractory high-risk neuroblastoma","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"42dbb8bb-1a7a-5125-9334-dc9976f08e90","evidence_kind":"source_excerpt","locator":"Lines 346-357","start_line":346,"end_line":357,"excerpt":"### bg-dose-did-not-track-response\nOne patient developed a dose-limiting toxicity of transient self-limiting hepatic transaminase elevation 5 days after starting beta-glucan at 120 milligrams per kilogram per day, overall 1, 3, 12 and 24 evaluable patients had complete response, partial response, stable and progressive disease respectively at the end of treatment, positive human anti-mouse antibody response and dectin-1 rs3901533 polymorphism were associated with better overall survival, and beta-glucan dose level and serum beta-glucan levels did not correlate with response.\nCondition category: normal\nnutrient_topic: Beta-glucan research collection; topical membership is not evidence of a direct clinical effect, and each preparation is recorded as its own entity with no family link joining any pair.\nplain_language: Across a twentyfold range of doses, how much was taken did not predict who responded; a receptor gene variant did.\norganism: Human\ntissue_or_cell_type: Relapsed or refractory high-risk neuroblastoma\nexperimental_model: Phase I dose escalation of oral yeast glucan with an anti-GD2 antibody across cohorts of three to six patients\nlimitations: A single-arm phase I with no control for the antibody alone, so the glucan contribution to any response cannot be isolated. Forty-four patients completed 141 cycles and forty were evaluable at end of treatment.\nexposure: Oral yeast beta-glucan escalated from 10 to 200 milligrams per kilogram per day for 17 days with intravenous 3F8 antibody\nevidence_span: {\"source_cache\": \"artifacts/glucan-research/34944886.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"ebbaee1e57b37044ff51d85d98d519101169e09a734d420c8bce53faab1d19f0\", \"start_char\": 0, \"end_char\": 1471, \"text_sha256\": \"ebbaee1e57b37044ff51d85d98d519101169e09a734d420c8bce53faab1d19f0\"}\n[bg-p34944886] Phase I Trial of Oral Yeast-Derived β-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk Neuroblastoma. (2021). https://pubmed.ncbi.nlm.nih.gov/34944886/ DOI: 10.3390/cancers13246265","model_system":"Phase I dose escalation of oral yeast glucan with an anti-GD2 antibody across cohorts of three to six patients","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [bg-p34944886] Phase I Trial of Oral Yeast-Derived β-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk Neuroblastoma. (2021). https://pubmed.ncbi.nlm.nih.gov/34944886/ DOI: 10.3390/cancers13246265","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"74dc223d-8289-57bf-a731-d220fa017c1e","stable_key":"import-10629adf-a816-5b7b-82db-a76bfbb946f2","title":"Beta-glucan: a structural family rather than an agent, what decides whether a bound glucan actually signals, the complement route that a cereal and a yeast preparation share, and the unequal human evidence behind each (2026-09-22)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"7c62f2d2f8d99b650e6dc26a505b0f053ae1c8bdb38099d4dfc0771f65287461","revision_id":"a53bb794-0a4b-525d-9cf7-22b46a5403b0","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}